101 related articles for article (PubMed ID: 28453835)
1. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
Celum C; Hong T; Cent A; Donnell D; Morrow R; Baeten JM; Firnhaber C; Grinsztejn B; Hosseinipour MC; Lalloo U; Nyirenda M; Riviere C; Sanchez J; Santos B; Supparatpinyo K; Hakim J; Kumarasamy N; Campbell TB;
J Infect Dis; 2017 Mar; 215(6):907-910. PubMed ID: 28453835
[TBL] [Abstract][Full Text] [Related]
2. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
[TBL] [Abstract][Full Text] [Related]
4. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
Marcus JL; Glidden DV; McMahan V; Lama JR; Mayer KH; Liu AY; Montoya-Herrera O; Casapia M; Hoagland B; Grant RM
PLoS One; 2014; 9(3):e91513. PubMed ID: 24637511
[TBL] [Abstract][Full Text] [Related]
5. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Tan DH; Kaul R; Raboud JM; Walmsley SL
AIDS; 2011 Jan; 25(2):207-10. PubMed ID: 21150556
[TBL] [Abstract][Full Text] [Related]
6. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
Bender Ignacio RA; Perti T; Magaret AS; Rajagopal S; Stevens CE; Huang ML; Selke S; Johnston C; Marrazzo J; Wald A
J Infect Dis; 2015 Dec; 212(12):1949-56. PubMed ID: 26044291
[TBL] [Abstract][Full Text] [Related]
7. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
[TBL] [Abstract][Full Text] [Related]
8. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
9. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).
Barnabas RV; Wasserheit JN; Huang Y; Janes H; Morrow R; Fuchs J; Mark KE; Casapia M; Mehrotra DV; Buchbinder SP; Corey L;
J Acquir Immune Defic Syndr; 2011 Jul; 57(3):238-44. PubMed ID: 21860356
[TBL] [Abstract][Full Text] [Related]
10. Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.
Tyo KM; Vuong HR; Malik DA; Sims LB; Alatassi H; Duan J; Watson WH; Steinbach-Rankins JM
Int J Pharm; 2017 Oct; 531(1):118-133. PubMed ID: 28797967
[TBL] [Abstract][Full Text] [Related]
11. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
12. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
[TBL] [Abstract][Full Text] [Related]
15. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Mofenson LM; Baggaley RC; Mameletzis I
AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Andrei G; Gillemot S; Topalis D; Snoeck R
J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
20. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
Celum CL; Robinson NJ; Cohen MS
J Infect Dis; 2005 Feb; 191 Suppl 1():S107-14. PubMed ID: 15627220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
